Search Results - "HOPPENREIJS, E"

Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register by Prince, F H M, Twilt, M, ten Cate, R, van Rossum, M A J, Armbrust, W, Hoppenreijs, E P A H, van Santen-Hoeufft, M, Koopman-Keemink, Y, Wulffraat, N M, van Suijlekom-Smit, L W A

“…We undertook an observational study to obtain a complete overview of the long-term effectiveness and safety of etanercept in patients with different juvenile…”
Get more information

Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease by Mertens, J.S., Seyger, M.M.B., Kievit, W., Hoppenreijs, E.P.A.H., Jansen, T.L.Th.A., van de Kerkhof, P.C.M., Radstake, T.R.D., de Jong, E.M.G.J.

“…Summary Background Localized scleroderma (LoS) is characterized by a phase of disease activity followed by remission. However, disease recurrences occur…”
Get full text

The identification of CCL18 as biomarker of disease activity in localized scleroderma by Mertens, J.S., de Jong, E.M.G.J., van den Hoogen, L.L., Wienke, J., Thurlings, R.M., Seyger, M.M.B., Hoppenreijs, E.P.A.H., Wijngaarde, C.A., van Vlijmen-Willems, I.M.J.J., van den Bogaard, E., Giovannone, B., van Wijk, F., van Royen-Kerkhof, A., Marut, W., Radstake, T.R.D.

“…Localized Scleroderma (LoS) encompasses a group of idiopathic skin conditions characterized by (sub)cutaneous inflammation and subsequent development of…”
Get full text

CD226 (DNAM-1) is associated with susceptibility to juvenile idiopathic arthritis by Reinards, T H C M, Albers, H M, Brinkman, D M C, Kamphuis, S S M, van Rossum, M A J, Girschick, H J, Wouters, C, Hoppenreijs, E P A H, Saurenmann, R K, Hinks, A, Ellis, J A, Bakker, E, Verduijn, W, Slagboom, P, Huizinga, T W J, Toes, R E M, Houwing-Duistermaat, J J, ten Cate, R, Schilham, M W

“…Juvenile idiopathic arthritis (JIA) is considered a complex genetic autoimmune disease. We investigated the association of genetic variants previously…”
Get more information

Regarding “Transcriptional and Cytokine Profiles Identify CXCL9 as a Biomarker of Disease Activity in Morphea” by Mertens, J.S., de Jong, E.M.G.J., Pandit, A., Seyger, M.M.B., Hoppenreijs, E.P.A.H., Thurlings, R.M., Vonk, M.C., Wienke, J., van Wijk, F., van Royen-Kerkhof, A., Marut, W., Radstake, T.R.D.

Get full text

Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study by de Jager, Wilco, Hoppenreijs, Esther P A H, Wulffraat, Nico M, Wedderburn, Lucy R, Kuis, Wietse, Prakken, Berent J

“…Background: Juvenile idiopathic arthritis (JIA) consists of a heterogeneous group of disorders with, for the most part, an unknown immunopathogenesis. Although…”
Get full text

Methotrexate in pediatric plaque-type psoriasis: Long-term daily clinical practice results from the Child-CAPTURE registry by Geel, M. J. van, Oostveen, A. M., Hoppenreijs, E. P. A. H., Hendriks, J. C. M., Kerkhof, P. C. M. van de, de Jong, E. M. G. J., Seyger, M. M. B.

“…Background: Evidence on effectiveness and safety of methotrexate (MTX) in pediatric psoriasis is scarce. Objectives: To study the effectiveness and safety of…”
Get full text

Genetic variation in VTCN1 (B7-H4) is associated with course of disease in juvenile idiopathic arthritis by Albers, H M, Reinards, T H C M, Brinkman, D M C, Kamphuis, S S M, van Rossum, M A J, Hoppenreijs, E P A H, Girschick, H J, Wouters, C, Saurenmann, R K, Bakker, E, Verduijn, W, Slagboom, P, Huizinga, T W J, Toes, R E M, Houwing-Duistermaat, J J, ten Cate, R, Schilham, M W

“…The course of disease in juvenile idiopathic arthritis (JIA) is unpredictable with episodes of activity and remission. In order to identify predictive factors,…”
Get more information

Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis by Prince, F H M, Geerdink, L M, Borsboom, G J J M, Twilt, M, van Rossum, M A J, Hoppenreijs, E P A H, Cate, R Ten, Koopman-Keemink, Y, van Santen-Hoeufft, M, Raat, H, van Suijlekom-Smit, L W A

“…To evaluate changes in health-related quality of life (HRQoL) in patients with refractory juvenile idiopathic arthritis (JIA) who are being treated with…”
Get more information

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis by Prince, F H M, Twilt, M, Simon, S C M, van Rossum, M A J, Armbrust, W, Hoppenreijs, E P A H, Kamphuis, S, van Santen-Hoeufft, M, Koopman-Keemink, Y, Wulffraat, N M, ten Cate, R, van Suijlekom-Smit, L W A

Get more information

Quantitative muscle ultrasound: a potential tool for assessment of disease activity in juvenile dermatomyositis by Bhansing, KJ, Hoppenreijs, EP, Janssen, AJ, van Royen-Kerkhof, A, Nijhuis-Van der Sanden, MW, van Riel, PLCM, Pillen, S

Get full text

Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients by Muller, P C E Hissink, Anink, J, Shi, J, Levarht, E W N, Reinards, T H C M, Otten, M H, van Tol, M J D, Jol-van der Zijde, C M, Brinkman, D M C, Allaart, C F, Hoppenreijs, E P, Koopman-Keemink, Y, Kamphuis, S S M, Dolman, K, van den Berg, J M, van Rossum, M A J, van Suijlekom-Smit, L W A, Schilham, M W, Huizinga, T W J, Toes, R E M, Ten Cate, R, Trouw, L A

Get more information

Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis by Albers, H. M., Brinkman, D. M. C., Kamphuis, S. S. M., van Suijlekom‐Smit, L. W. A., van Rossum, M. A. J., Hoppenreijs, E. P. A. H., Girschick, H. J., Wouters, C., Saurenmann, R. K., Houwing‐Duistermaat, J. J., Huizinga, T. W. J., Schilham, M. W., ten Cate, R.

“…Objective Juvenile idiopathic arthritis (JIA) is a heterogeneous disease involving chronic arthritis. The clinical course is characterized by a fluctuating…”
Get full text

Development of a web-based register for the Dutch national study on biologicals in JIA: www.ABC-register.nl by Prince, F. H. M., Ferket, I. S., Kamphuis, S., Armbrust, W., ten Cate, R., Hoppenreijs, E. P. A. H., Koopman-Keemink, Y., van Rossum, M. A. J., van Santen-Hoeufft, M., Twilt, M., van Suijlekom-Smit, L. W. A.

“…Objectives. Most clinical studies use paper case record forms (CRFs) to collect data. In the Dutch multi-centre observational study on biologicals we…”
Get full text

Hereditary C1q deficiency and secondary Sjögren’s syndrome by Hoppenreijs, E P A H, van Dijken, P J, Kabel, P J, Th Draaisma, J M

Get full text

Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis by Heijstek, Marloes W, Pileggi, Gecilmara C S, Zonneveld-Huijssoon, Evelien, Armbrust, Wineke, Hoppenreijs, Esther P A H, Uiterwaal, Cuno S P M, Kuis, Wietse, Wulffraat, Nico M

“…Objective:To assess the effect of measles, mumps and rubella (MMR) vaccination on disease activity in children with juvenile idiopathic arthritis…”
Get full text

Phenotypic variability including Behçet's disease-like manifestations in DADA2 patients due to a homozygous c.973-2A>G splice site mutation by van Well, Gijs T J, Kant, Benjamin, van Nistelrooij, Annabel, Sirma Ekmekci, Sema, Henriet, Stefanie V, Hoppenreijs, Esther, van Deuren, Marcel, van Montfrans, Joris, Nierkens, Stefan, Gül, Ahmet, van Gijn, Mariëlle E

“…To describe phenotypic and functional characteristics of patients with the homozygous c.973-2A>G splice site mutation in the adenosine deaminase 2 (ADA2) gene…”
Get full text

Use of Mycophenolate Mofetil in Patients with Severe Localized Scleroderma Resistant or Intolerant to Methotrexate by Mertens, Jorre S, Marsman, Diane, van de Kerkhof, Peter C M, Hoppenreijs, Esther P A H, Knaapen, Hanneke K A, Radstake, Timothy R D, de Jong, Elke M G J, Seyger, Marieke M B

“…To assess the efficacy and safety of mycophenolate mofetil (MMF) in patients with localized scleroderma (LoS) resistant or intolerant to previous treatment…”
Get full text

Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? by Anink, Janneke, Otten, Marieke H, Gorter, Simone L, Prince, Femke H M, van Rossum, Marion A J, van den Berg, J Merlijn, van Pelt, Philomine A, Kamphuis, Sylvia, Brinkman, Danielle M C, Swen, Wijnand A A, Swart, Joost F, Wulffraat, Nico M, Dolman, Koert M, Koopman-Keemink, Yvonne, Hoppenreijs, Esther P A H, Armbrust, Wineke, ten Cate, Rebecca, van Suijlekom-Smit, Lisette W A

“…To evaluate differences in baseline characteristics between etanercept- and adalimumab-treated JIA patients and to reveal factors that influence the choice…”
Get full text

Association of the autoimmunity locus 4q27 with juvenile idiopathic arthritis by Albers, H. M., Kurreeman, F. A. S., Stoeken‐Rijsbergen, G., Brinkman, D. M. C., Kamphuis, S. S. M., van Rossum, M. A. J., Girschick, H. J., Wouters, C., Saurenmann, R. K., Hoppenreijs, E., Slagboom, P., Houwing‐Duistermaat, J. J., Verduijn, W., Huizinga, T. W. J., ten Cate, R., Toes, R. E. M., Schilham, M. W.

“…Objective Juvenile idiopathic arthritis (JIA) is characterized by chronic arthritis and an autoimmune etiology. In several autoimmune diseases, including…”
Get full text